TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.530nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.590nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.690nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.730nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.840nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 0.950nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.70nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 1.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 2.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.10nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 3.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 4.90nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.30nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 5.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 6.5nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7.40nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 7.60nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 8.20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 8.80nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 11nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 11nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 12nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 13nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 14nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 14nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 16nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 17nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 18nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 19nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 19nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 20nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair
TargetTransient receptor potential M8 protein(Canis lupus familiaris (Dog))
Janssen Pharmaceutica
US Patent
Janssen Pharmaceutica
US Patent
Affinity DataIC50: 22nMT: 2°CAssay Description:HEK293 cells stably expressing canine TRPM8 were routinely grown as monolayers in Dulbecco's minimum essential medium supplemented with 10% FBS, ...More data for this Ligand-Target Pair